Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Pfizer

Status and phase: Completed; Phase 2; Phase 1

Conditions: Neoplasms; Adenocarcinoma

Treatments: Drug: Torisel

Study type: Interventional

Funder types: Industry

Identifiers

NCT00106353

3066K1-139

Details and patient eligibility

About

This is an open label, two-part study of temsirolimus given as a 60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors.

Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity. (recruiting)

Enrollment: 71 patients

Sex: All

Ages: 1 to 21 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Inclusion Criteria:

Part 1 only:

• Subjects with a histological diagnosis of advanced cancer (solid tumors or central nervous system [CNS] tumors) with disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available (histological confirmation waived for brain stem gliomas and optic pathway tumors)

Part 2 only:

• Subjects with histologically confirmed diagnosis of refractory or relapsed: Neuroblastoma, High-grade gliomas: glioblastoma multiforme, anaplastic astrocytomas, and other high-grade gliomas (histological confirmation waived for brain stem gliomas), Rhabdomyosarcoma.
• Measurable disease (for subjects with neuroblastoma, evaluable disease as determined by a positive metaiodobenzylguanidine (MIBG) scan will also be permitted).

Exclusion criteria

Exclusion Criteria:

• Subjects receiving enzyme-inducing anticonvulsants.
• Pulmonary hypertension or pneumonitis
• Active infection or serious intercurrent illness
• Other exclusions apply

Trial design

71 participants in 1 patient group

1.0

Experimental group

Treatment:

Drug: Torisel